Poor
Not Aligned
Patient Risk:
Medium
Summary
Most statements are about non-label/regulatory status and other indications (e.g., Japan approvals) and are not supported by the provided FDA ANZUPGO (delgocitinib) cream prescribing information excerpts. Only mechanistic JAK inhibitor description and general facts about development are partially label-consistent, but key label-specific indication/dosing are not evaluated and several unsupported regulatory/approval claims are included.
Category Scores
Accurate Statements
Delgocitinib is an investigational Janus kinase (JAK) inhibitor.
Label text provided does not state “investigational,” but mechanism is consistent with JAK inhibition: “Delgocitinib, a Janus kinase (JAK) inhibitor…” (12.1). The “investigational” characterization is not supported by the provided label excerpts.
Delgocitinib is a non-selective inhibitor of JAK family kinases.
Mechanism lists inhibition of multiple JAKs: “inhibits… JAK1, JAK2, JAK3, and TYK2” (12.1). The term “non-selective” is not exact label wording but is directionally consistent with multi-kinase inhibition.
By inhibiting JAK family kinases, delgocitinib modulates the immune response and reduces inflammation.
The provided excerpts do not explicitly state “reduces inflammation” or “modulates immune response.” Only the mechanism statement is provided (12.1). This statement is not directly supported by the provided label text.
Delgocitinib is being investigated for dermatological conditions including atopic dermatitis.
The provided FDA label excerpts provided are for chronic hand eczema (CHE) and do not mention atopic dermatitis as an indication (1 INDICATIONS AND USAGE). No support for “investigated for atopic dermatitis.”
Torii Pharmaceutical Co., Ltd. is developing delgocitinib.
No sponsor/manufacturer/developer information is included in the provided prescribing information excerpts.
Unsupported Statements
In Japan, delgocitinib has been approved for the treatment of atopic dermatitis.
Not supported by the provided FDA ANZUPGO (delgocitinib) cream label excerpts; label provided only indicates topical treatment of chronic hand eczema in adults (1 INDICATIONS AND USAGE).
In Japan, delgocitinib has been approved for the treatment of chronic plaque psoriasis.
Not supported by the provided FDA label excerpts; no psoriasis indication is stated in the provided label (1 INDICATIONS AND USAGE).
In Japan, delgocitinib has been approved for pruritus associated with atopic dermatitis and chronic plaque psoriasis.
Not supported by the provided FDA label excerpts; no pruritus indication is stated in the provided label (1 INDICATIONS AND USAGE).
Approval of delgocitinib in the United States is still under review for atopic dermatitis.
Regulatory status for US approvals beyond the provided FDA label excerpts is not addressed; also the provided label indication is chronic hand eczema (1 INDICATIONS AND USAGE).
Approval of delgocitinib in Europe is still under review for atopic dermatitis.
Not supported by the provided FDA label excerpts.
Delgocitinib is being investigated for dermatological conditions including atopic dermatitis.
Provided label excerpts do not mention atopic dermatitis as an investigated/indicated dermatologic condition.
Delgocitinib is being investigated for dermatological conditions including plaque psoriasis.
Provided label excerpts do not mention plaque psoriasis.
Delgocitinib has shown promise in treating hand eczema.
The label indicates ANZUPGO is for moderate to severe chronic hand eczema (1 INDICATIONS AND USAGE), but the claim is vague (“shown promise”) and is not directly phrased in label language.
By inhibiting JAK family kinases, delgocitinib modulates the immune response and reduces inflammation.
The provided mechanism section states JAK inhibition but does not explicitly include “modulates the immune response” or “reduces inflammation.”
Torii Pharmaceutical Co., Ltd. is developing delgocitinib.
No developer/manufacturer information is included in the provided prescribing information excerpts.
Contradictions
Low
AI Statement
Approval of delgocitinib in the United States is still under review for atopic dermatitis.
Label Reference
Provided FDA label excerpts show an FDA-approved product indication for chronic hand eczema in adults (1 INDICATIONS AND USAGE). The statement asserts US “under review for atopic dermatitis,” which is inconsistent with the provided label containing an approved indication (though not for atopic dermatitis).
Important Omissions
The FDA label-specific indication and limitations are not addressed in the AI response (e.g., indication is topical treatment of moderate to severe chronic hand eczema in adults; limitations with other JAK inhibitors/immunosuppressants).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While the response does not provide dosing/safety instructions, it makes multiple unsupported regulatory/indication claims (ATD/psoriasis/pruritus). Mismatch of indication could lead to inappropriate assumptions about use. The response also does not mention key FDA label safety elements (infection risk, herpes zoster/reactivation, non-melanoma skin cancer, immunization guidance).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported or non-label regulatory/indication claims (Japan approvals; US/EU review status for atopic dermatitis; psoriasis/pruritus indications) that are not supported by the provided FDA prescribing information.
Suggested Improvement
Limit statements to what is explicitly supported by the provided FDA ANZUPGO (delgocitinib) cream label excerpts—specifically the labeled indication (moderate to severe chronic hand eczema in adults), topical use/dosing limits and administration instructions, and labeled warnings/precautions (serious infections/herpes virus reactivation, non-melanoma skin cancer, immunization requirements), and avoid country-specific approval status claims unless present in the provided label.